Brocker.Org: Is Vertex’s New CF Drug Incremental? Unprecedented? Pricey? Maybe All A few. – Forbes

0
37


Forbes

Is Vertex’s New CF Drug Incremental? Unprecedented? Pricey? Maybe All A few.
Forbes
Shares in Boston’s Vertex Prescribed drugs are up 22% to $109 soon after the biotechnology corporation released info on an experimental mixture pill to address cystic fibrosis, a genetic disorder that shortens sufferers life by influencing their lungs and
Vertex Pharma shares soar 23% as corporation ups its cystic fibrosis offeringsMarketWatch
Vertex Combo Data on Kalydeco+VX-661 Favourable in Stage IIINasdaq
Vertex Rockets To 14-Month High On Cystic Fibrosis Drug SuccessInvestor’s Company Day by day
The Boston GlobeBioPharma DiveSmarter AnalystIrish Periods
all eighty three information posts »

LEAVE A REPLY

*